ERBB2 and inflammatory breast carcinoma: Frequent genomic alterations in the PI3K/AKT/mTOR pathway have been seen15, and somatic activation of this pathway (i.e., PIK3CA activating mutation or gain14, ERBB2 activating mutation, PTEN deletion, AKT1 activating mutation) was significantly associated with shorter progression-free survival (PFS) in trastuzumab-naïve HER2-positive IBC patients19.